NEWS RELEASE

Department of War
Defense Health Agency Research and Development-Medical Research and Development Command
Congressionally Directed Medical Research Programs

Released: February 4, 2026

CDMRP Announces $1.27 Billion, 34 Research Programs for Fiscal Year 2026

Congressional funding to the CDMRP supports research to advance solutions for diseases, conditions, and injuries impacting Service Members, their Families, Veterans, and the American public.

FORT DETRICK, Md. - On February 3, 2026, the President signed into law the "Consolidated Appropriations Act, 2026," which includes $1.27 billion in appropriations for 34 research funding programs managed by the CDMRP.

The fiscal year 2026 appropriated programs include:

• Alcohol and Substance Use Disorders Research Program - $4.0 million
• Alzheimer’s Research Program - $15.0 million
• Amyotrophic Lateral Sclerosis Research Program - $40.0 million
• Arthritis Research Program - $10.0 million
• Autism Research Program - $8.0 million
• Bone Marrow Failure Disease Research Program - $7.5 million
• Breast Cancer Research Program - $145.0 million
• Combat Readiness Medical Research Program - $5.0 million
• Duchenne Muscular Dystrophy Research Program - $12.5 million
• Epilepsy Research Program - $12.0 million
• Hearing Restoration Research Program - $5.0 million
• Joint Warfighter Medical Research Program - $10.0 million
• Kidney Cancer Research Program - $15.0 million
• Lung Cancer Research Program - $20.0 million
• Lupus Research Program - $10.0 million
• Melanoma Research Program - $40.0 million
• Military Burn Research Program - $10.0 million
• Multiple Sclerosis Research Program - $15.0 million
• Neurofibromatosis Research Program - $25.0 million
• Orthopaedic Research Program - $20.0 million
• Ovarian Cancer Research Program - $50.0 million
• Pancreatic Cancer Research Program - $20.0 million
• Parkinson’s Research Program - $16.0 million
• Peer Reviewed Cancer Research Program, 20 topics - $165.0 million
• Peer Reviewed Medical Research Program, 52 topics - $370.0 million
• Prostate Cancer Research Program - $75.0 million
• Rare Cancers Research Program - $17.5 million
• Reconstructive Transplant Research Program - $12.0 million
• Spinal Cord Injury Research Program - $33.0 million
• Tick-Borne Disease Research Program - $7.0 million
• Toxic Exposures Research Program - $15.0 million
• Traumatic Brain Injury and Psychological Health Research Program - $40.5 million
• Tuberous Sclerosis Complex Research Program - $10.0 million
• Vision Research Program - $10.0 million

The CDMRP will release pre-announcements and funding opportunity announcements as soon as available for each program. Pre-announcements provide a brief overview of anticipated award mechanisms within each program and are posted to the CDMRP website at https://cdmrp.health.mil. Funding opportunity announcements include detailed descriptions of award mechanism intent, evaluation criteria, submission requirements, and deadlines. The CDMRP posts funding opportunity announcements on the CDMRP website at https://cdmrp.health.mil, on Grants.gov at https://www.grants.gov, and on eBRAP at https://eBRAP.org. All applications must conform to the final funding opportunity announcements that will be available for downloading from Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA number 12.420.

To receive email notifications following release of pre-announcements and funding opportunity announcements, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage.

For more information about the CDMRP, our research programs, and research highlights, please visit the website at https://cdmrp.health.mil.

Point of Contact:
CDMRP Public Affairs
301-619-7071
dha.detrick.cdmrp.mbx.public-affairs@health.mil

Top of Page